Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase NA 2Phase 2 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 890NETWORK 114NIH 109INDUSTRY 54OTHER_GOV 5UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Extranodal NK-T-Cell 1

Interventions

S 1 (combination) 12Capecitabine 11Paclitaxel 9Cisplatin 9apatinib 8Oxaliplatin 8pyrotinib 6nimotuzumab 6130-nm albumin-bound paclitaxel 6titanium silicide 5sintilimab 5camrelizumab 5anlotinib 5Etoposide 5Docetaxel 5Carboplatin 5Trastuzumab 4Radiotherapy, Intensity-Modulated 4Irinotecan 4Bevacizumab 4Albumin-Bound Paclitaxel 4nedaplatin 3Vinorelbine 3Temozolomide 3Tegafur 3Taxes 3Radiosurgery 3Gemcitabine 3Fluorouracil 3Epirubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × UNKNOWN × Radiotherapy × Clear all
NCT05149170 2021-12-08

Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL

ChineseAMS

Phase 2 Unknown
30 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡